No Data
No Data
Express News | Relmada- to Pay up to $200 Mln in Development, Regulatory,Sales Milestones Pending Successful Commercialization
Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
Express News | Relmada- Under Deal,Co to Make $3.5 Mln Upfront Payment and Issue 3,017,420 Shares of Common Stock
Express News | Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, Ndv-01, From Trigone Pharma, Ltd.
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, From Trigone Pharma, Ltd.
RELMADA THERAPEUTICS Earnings Preview: Recent $RLMD Insider Trading, Hedge Fund Activity, and More
72618070 : why?
74534891 : No, it will rise to at most today.1.x